These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
409 related items for PubMed ID: 11030149
21. Synergistic induction of apoptosis in neuroblastoma cells using a combination of cytostatic drugs with interferon-gamma and TRAIL. Johnsen JI, Pettersen I, Ponthan F, Sveinbjørnsson B, Flaegstad T, Kogner P. Int J Oncol; 2004 Dec; 25(6):1849-57. PubMed ID: 15547726 [Abstract] [Full Text] [Related]
22. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand. Mitsiades N, Poulaki V, Tseleni-Balafouta S, Koutras DA, Stamenkovic I. Cancer Res; 2000 Aug 01; 60(15):4122-9. PubMed ID: 10945619 [Abstract] [Full Text] [Related]
23. Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. MacFarlane M, Harper N, Snowden RT, Dyer MJ, Barnett GA, Pringle JH, Cohen GM. Oncogene; 2002 Oct 03; 21(44):6809-18. PubMed ID: 12360407 [Abstract] [Full Text] [Related]
24. Butyrate sensitizes human colon cancer cells to TRAIL-mediated apoptosis. Hernandez A, Thomas R, Smith F, Sandberg J, Kim S, Chung DH, Evers BM. Surgery; 2001 Aug 03; 130(2):265-72. PubMed ID: 11490359 [Abstract] [Full Text] [Related]
25. Inhibition of DNA methylation sensitizes glioblastoma for tumor necrosis factor-related apoptosis-inducing ligand-mediated destruction. Eramo A, Pallini R, Lotti F, Sette G, Patti M, Bartucci M, Ricci-Vitiani L, Signore M, Stassi G, Larocca LM, Crinò L, Peschle C, De Maria R. Cancer Res; 2005 Dec 15; 65(24):11469-77. PubMed ID: 16357155 [Abstract] [Full Text] [Related]
26. TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bcl-2. Munshi A, Pappas G, Honda T, McDonnell TJ, Younes A, Li Y, Meyn RE. Oncogene; 2001 Jun 28; 20(29):3757-65. PubMed ID: 11439339 [Abstract] [Full Text] [Related]
27. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance. Ng CP, Zisman A, Bonavida B. Prostate; 2002 Dec 01; 53(4):286-99. PubMed ID: 12430140 [Abstract] [Full Text] [Related]
28. Regulation of the resistance to TRAIL-induced apoptosis as a new strategy for pancreatic cancer. Mori T, Doi R, Toyoda E, Koizumi M, Ito D, Kami K, Kida A, Masui T, Kawaguchi Y, Fujimoto K. Surgery; 2005 Jul 01; 138(1):71-7. PubMed ID: 16003319 [Abstract] [Full Text] [Related]
29. Human hepatocellular carcinoma cells resist to TRAIL-induced apoptosis, and the resistance is abolished by cisplatin. Shin EC, Seong YR, Kim CH, Kim H, Ahn YS, Kim K, Kim SJ, Hong SS, Park JH. Exp Mol Med; 2002 May 31; 34(2):114-22. PubMed ID: 12085986 [Abstract] [Full Text] [Related]
30. Analysis of FasL and TRAIL induced apoptosis pathways in glioma cells. Knight MJ, Riffkin CD, Muscat AM, Ashley DM, Hawkins CJ. Oncogene; 2001 Sep 13; 20(41):5789-98. PubMed ID: 11593384 [Abstract] [Full Text] [Related]
31. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II. Ravi R, Bedi A. Cancer Res; 2002 Aug 01; 62(15):4180-5. PubMed ID: 12154014 [Abstract] [Full Text] [Related]
32. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. Lacour S, Hammann A, Wotawa A, Corcos L, Solary E, Dimanche-Boitrel MT. Cancer Res; 2001 Feb 15; 61(4):1645-51. PubMed ID: 11245478 [Abstract] [Full Text] [Related]
33. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Ganten TM, Haas TL, Sykora J, Stahl H, Sprick MR, Fas SC, Krueger A, Weigand MA, Grosse-Wilde A, Stremmel W, Krammer PH, Walczak H. Cell Death Differ; 2004 Jul 15; 11 Suppl 1():S86-96. PubMed ID: 15105837 [Abstract] [Full Text] [Related]
34. Death receptor 4 (DR4) efficiently kills breast cancer cells irrespective of their sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Kazhdan I, Marciniak RA. Cancer Gene Ther; 2004 Oct 15; 11(10):691-8. PubMed ID: 15354201 [Abstract] [Full Text] [Related]
35. Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell carcinoma. Griffith TS, Fialkov JM, Scott DL, Azuhata T, Williams RD, Wall NR, Altieri DC, Sandler AD. Cancer Res; 2002 Jun 01; 62(11):3093-9. PubMed ID: 12036919 [Abstract] [Full Text] [Related]
36. Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio. Mühlethaler-Mottet A, Flahaut M, Bourloud KB, Auderset K, Meier R, Joseph JM, Gross N. BMC Cancer; 2006 Aug 24; 6():214. PubMed ID: 16930472 [Abstract] [Full Text] [Related]
37. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria. Zhang XD, Zhang XY, Gray CP, Nguyen T, Hersey P. Cancer Res; 2001 Oct 01; 61(19):7339-48. PubMed ID: 11585775 [Abstract] [Full Text] [Related]
38. Signaling events triggered by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): caspase-8 is required for TRAIL-induced apoptosis. Seol DW, Li J, Seol MH, Park SY, Talanian RV, Billiar TR. Cancer Res; 2001 Feb 01; 61(3):1138-43. PubMed ID: 11221844 [Abstract] [Full Text] [Related]
39. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling. Chen X, Kandasamy K, Srivastava RK. Cancer Res; 2003 Mar 01; 63(5):1059-66. PubMed ID: 12615723 [Abstract] [Full Text] [Related]
40. Human retinoblastoma cells are resistant to apoptosis induced by death receptors: role of caspase-8 gene silencing. Poulaki V, Mitsiades CS, McMullan C, Fanourakis G, Negri J, Goudopoulou A, Halikias IX, Voutsinas G, Tseleni-Balafouta S, Miller JW, Mitsiades N. Invest Ophthalmol Vis Sci; 2005 Jan 01; 46(1):358-66. PubMed ID: 15623796 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]